Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

306
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
306
Viral Mutations00:36

Viral Mutations

32.3K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH-1 multicentre cohort study.

HIV medicine·2026
Same author

Identification and functional characterization of regulatory variants in DPP9 associated with COVID-19 severity.

Genome medicine·2026
Same author

Overlooked risk factors for European autochthonous strongyloidiasis, Paris, France.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program <sup>a</sup>.

Open forum infectious diseases·2026
Same author

Expansion of NKG2A<sup>+</sup>CD8<sup>+</sup> T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1.

Med (New York, N.Y.)·2026
Same author

Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.

The lancet. HIV·2026

Related Experiment Video

Updated: Jul 2, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

[Updates in HIV infection therapeutics].

Marie Gilbert1, Yazdan Yazdanpanah2, Jade Ghosn3

  • 1Service des maladies infectieuses et tropicales, hôpital Bichat-Claude-Bernard, AP-HP, Paris, France.

La Revue Du Praticien
|February 28, 2024
PubMed
Summary
This summary is machine-generated.

Human immunodeficiency virus (HIV) infection remains a global health concern, driving continuous therapeutic innovation. Current treatments significantly reduce HIV-related illness and death, shifting focus to prevention and improved patient quality of life.

Keywords:
HIV Infections

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.4K

Related Experiment Videos

Last Updated: Jul 2, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.4K

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Context:

  • Human immunodeficiency virus (HIV) infection presents ongoing global health challenges.
  • Advances in antiretroviral therapy have dramatically improved patient outcomes.
  • Current treatment paradigms focus on managing chronic infection and preventing transmission.

Purpose:

  • To review recent therapeutic innovations in the management of HIV infection.
  • To highlight new strategies for transmission prevention and side effect reduction.
  • To discuss improvements in the quality of life for individuals living with HIV.

Summary:

  • The landscape of HIV therapeutics is rapidly evolving with new drug classes and treatment modalities.
  • Focus has shifted from solely managing viral load to a holistic approach encompassing prevention, toxicity, and quality of life.
  • Innovations include novel molecules, updated treatment regimens, and enhanced prevention strategies.

Impact:

  • Significant reduction in HIV-related morbidity and mortality.
  • Improved long-term health and well-being for people living with HIV.
  • Potential for further reductions in HIV transmission and the burden of disease globally.